Document Type
Article
Publication Date
9-20-2022
Publication Title
npj Vaccines
Abstract
Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop’s findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
Volume
7
Issue
1
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Casper, Corey; Corey, Lawrence; Cohen, Jeffrey I.; Damania, Blossom; Gershon, Anne A.; Kaslow, David C.; Krug, Laurie T.; Martin, Jeffrey; Mbulaiteye, Sam M.; Mocarski, Edward S.; Moore, Patrick S.; Ogembo, Javier Gordon; Phipps, Warren; Whitby, Denise; and Wood, Charles, "KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine" (2022). School of Medicine Faculty Publications. 451.
https://digitalscholar.lsuhsc.edu/som_facpubs/451
File Format
File Size
1142 KB